Merck: Credit Suisse raises target price

(CercleFinance.com) - Credit Suisse reiterates its "outperform" rating on Merck & Co and has raised its target price the share from 71 dollars to 81 dollars, despite the significant (+25%)rise already recorded by the share of the US health group this year.


“We see room for additional upside as the company continues to roll out Keytruda, most notably in the 1st line non-small cell lung (NSCLC) setting,” the analyst confirms.

Credit Suisse recognizes that longer-term investors remain concerned about the expiry of the Januvia patent in mid-2022, although the broker has raised its EPS estimates from 4.71 dollars to 4.79 dollars for 2019 and from 5.17 dollars to 5.42 dollars for 2020.


Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.